Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals

Drug Profile

Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals

Alternative Names: 4-Hydroxy-N-desmethyltamoxifen; Z-endoxifen; Z-Endoxifen Hydrochloride

Latest Information Update: 28 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Intas Pharmaceuticals; Jina Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Methylamines; Phenyl ethers; Small molecules; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bipolar disorders
  • Phase II Breast cancer
  • No development reported Fibroma; Gynaecological cancer

Most Recent Events

  • 28 Nov 2021 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease, Neoadjuvant therapy) in USA (Topical, Gel)
  • 13 Sep 2021 Pharmacokinetics data from two phase I clinical trials presented at the 2021 American College of Clinical Pharmacology Annual Meeting (ACCP-2021) by National Cancer Institute
  • 28 Jul 2021 No recent reports of development identified for phase-I development in Fibroma in USA (PO, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top